Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)

Condition(s) studied

Investigational drug(s) / intervention(s)

AI: STRATIF-AI apps will be used as an integral part of the dialogue with patients during thesecondary prevention phase

healthy dialogue: Patients allocated to arm 2 will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA

Study summary

The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid angiopathy, including adults of both sexes.

The main questions it aims to answer is: how is the patients' experience regarding the use of the STRATIF-AI platform? Researchers will compare Arm 1, who use the STRATIF-AI app in addition to standard secondary prevention, against Arm 2, who receive standard secondary prevention only, to collect feedback regarding the platform usability.

Participants in the Arm 1 will:

* Complete cognitive and psychological assessments at the time of the first visit and after six months
* Follow the indications received from the clinician for standard secondary prevention
* Use the STRATIF-AI app daily for health management
* Optionally, purchase wearable devices that connect to the app.
* Participate in interviews at the six-month mark to share their experiences with the app.

Patients in the Arm 2 will:

* Complete cognitive and psychological assessments at the time of the first visit and after six months
* Follow the indications received from the clinician for standard secondary prevention

Eligibility

Primary outcome measure(s)

• Feedback from users — 12 months
  To get initial feedback on the patients' experience regarding the use of the STRATIF-AIplatform in the secondary prevention phase.

Trial sites (1)

More Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials in Italy

Other trials for the same condition